MetaCap

Biodexa Pharmaceuticals American Depositary Shs (BDRX) vs GeoVax Labs (GOVX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

GeoVax Labs is the larger company by market cap ($985,459 vs $982,950), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BDRX+232.56%GOVX+525.43%
+682%+292%-97%
Oct 7, 20261 yearNov 20, 2026
BDRX+307.43%GOVX+544.13%
+680%+301%-78%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BDRX versus GOVX key metrics
MetricBDRXGOVX
Share price$1.88$1.81
Market cap$982.95K$985.46K
1-day change-3.85%-5.24%
P/E ratio (TTM)0.00—
EPS (TTM)$509.89$-15.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.49M
Revenue growth (YoY)—-37.06%
Net income (latest FY)—$-21.46M
Operating margin—-869.34%
Net margin—-862.34%
52-week high$357.60$270.60
52-week low$1.85$1.51
Distance from 52-week high-99.48%-99.33%
Analyst consensusnonenone
Avg. price target upside+375.20%+452.49%
Average volume618.91K213.41K
Shares outstanding524.24K544.45K
Employees1119
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Biodexa Pharmaceuticals American Depositary Shs

BDRX stock →

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees

About GeoVax Labs

GOVX stock →

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

BDRX vs GOVX FAQ

Which is bigger, Biodexa Pharmaceuticals American Depositary Shs or GeoVax Labs?

GeoVax Labs (GOVX) is larger, with a market capitalization of $985.46K compared with $982.95K for Biodexa Pharmaceuticals American Depositary Shs (BDRX).

Are Biodexa Pharmaceuticals American Depositary Shs and GeoVax Labs in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons